VYNE Therapeutics Inc. - Common Stock (NQ:VYNE)

28.56 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about VYNE Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 10, 2023

Via Benzinga

Why Penny Stock VYNE Therapeutics Is Skyrocketing Today? ↗

January 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 10, 2023

Via Benzinga

Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket ↗

January 10, 2023

Gainers VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo patient was dosed in Phase 1a/b clinical trial of novel BET inhibitor...

Via Benzinga

VYNE Therapeutics: Q2 Earnings Insights ↗

August 12, 2022

VYNE Therapeutics (NASDAQ:VYNE) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114 ↗

April 07, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

January 10, 2023

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday!

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 09, 2023

Via Benzinga

Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 09, 2023

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

Via InvestorPlace

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 06, 2023

Via Benzinga

Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 05, 2023

Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 04, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 22, 2022

On Thursday, 1076 companies hit new 52-week lows.

Via Benzinga

VYNE Therapeutics Earnings Perspective: Return On Capital Employed ↗

September 09, 2022

VYNE Therapeutics (NASDAQ:VYNE) brought in sales totaling $126 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 281.5%, resulting in a loss of $8.48 million.

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 10, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 10, 2022

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday ↗

August 11, 2022

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.

Via Benzinga

VYNE Therapeutics Shares Plummet As Mid-Stage Skin Disease Study Missed Primary Endpoint ↗

August 10, 2022

VYNE Therapeutics Inc. (NASDAQ: VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

Via Benzinga

VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial ↗

August 10, 2022

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.

Via Benzinga

VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate ↗

June 17, 2022

VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 05, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 07, 2022

Gainers IMAC Holdings (NASDAQ:IMAC) shares increased by 60.0% to $1.6 during Thursday's pre-market session. The market value of their outstanding shares is at $41.9 million.

Via Benzinga

VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis ↗

March 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 18, 2022

Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares increased by 27.8% to $1.77 during Friday's regular session. The current volume of 149.1K shares is 551.4% of...

Via Benzinga

VYNE Therapeutics's Return On Capital Employed Insights ↗

March 18, 2022

According to data from Benzinga Pro, during Q4, VYNE Therapeutics's (NASDAQ:VYNE) reported sales totaled $2.29 million. Despite a 45.64% increase in earnings, the company posted a...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.